Kunovszki P, Milassin Á, Gimesi-Országh J, et al. Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010–2016 in Hungary – a population-based study. PLoS ONE 2020; 15: e0233238.
Burisch J, Katsanos KH, Christodoulou DK, et al. Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort – an Epi-IBD study. J Crohns Colitis 2019; 13: 198–208.
Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011; 17: 1314–1321.
Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749–753.
Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3–11.
Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009; 44: 431–440.
Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007; 13: 481–489.
Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174–178.
Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451–459.
Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905–910.
Jelsness-Jørgensen LP, Bernklev T, Moum B. Calprotectin is a useful tool in distinguishing coexisting irritable bowel-like symptoms from that of occult inflammation among inflammatory bowel disease patients in remission. Gastroenterol Res Pract. 2013; 2013: 620707.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 1625–1629.
Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013; 145: 987–995.
Barreiro-de Acosta M, Magro F, Carpio D, et al. Ulcerative colitis in northern Portugal and Galicia in Spain. Inflamm Bowel Dis. 2010; 16: 1227–1238.
Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10: 239–254.
Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis 2022; 16: 2–17.
Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010; (1): CD004115.
Osterman MT, Aberra FN, Cross R, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014; 12: 1887–1893.e3.
Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960; 1: 217–222.
Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143: 1218–1226.e2.
Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63: 433–441.
Sandborn WJ, Danese S, D’Haens G, et al. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015; 41: 409–418.
Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J. 1974; 4(5945): 627–630.
Sood A, Midha V, Sood N, et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol. 2000; 19: 14–16.
Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 590–600.
Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392–400.e3.
Bonovas S, Lytras T, Nikolopoulos G, et al. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis – what is best in class? Authors’ reply. Aliment Pharmacol Ther. 2018; 47: 540–541.
Singh S, Murad MH, Fumery M, et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020; 18: 2179–2191.e6.
Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369: 699–710.
Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022; 28: 32–40.
Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019; 381: 1201–1214.
Narula N, Marshall JK, Colombel JF, et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016; 111: 477–491.
Szemes K, Soós A, Hegyi P, et al. Comparable long-term outcomes of cyclosporine and infliximab in patients with steroid-refractory acute severe ulcerative colitis: a meta-analysis. Frontiers Med. 2020; 6: 338.
Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016: 1: 15–24.
Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007; 26: 747–756.
Sebastian S, Myers S, Argyriou K, et al. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther. 2019; 50: 675–683.
Narula N, Fine M, Colombel JF, et al. Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks? Inflamm Bowel Dis. 2015; 21: 1683–1694.
Fradet C, Kern J, Atanasov P, et al. Impact of surgery and its complications in ulcerative colitis patients in clinical practice: A systematic literature review of real-world evidence in Europe. Int J Surg. 2020; 22: 22–32.
Peyrin-Biroulet L, Germain A, Patel AS, et al. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2016: 44; 807–816.
Kuehn F, Hodin RA. Impact of modern drug therapy on surgery: ulcerative colitis. Visceral Med. 2018; 34: 426–431.
Lightner AL, Mathis KL, Dozois EJ, et al. Results at up to 30 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Inflamm Bowel Dis. 2017; 23: 781–790.
Murphy PB, Khot Z, Vogt KN, et al. Quality of life after total proctocolectomy with ileostomy or IPAA: a systematic review. Dis Colon Rectum 2015; 58: 899–908.
Adamina M, Gerasimidis K, Sigall-Boneh R, et al. Perioperative dietary therapy in inflammatory bowel disease. J Crohn’s Colitis 2020; 14: 431–444.
Forbes A, Escher J, Hébuterne X, et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr (Edinburgh, Scotland) 2017; 36: 321–347.
Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1. Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis 2017; 11: 649–670.
Kaplan GG, Lim A, Seow CH, et al. Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World J Gastroenterol. 2015; 21: 1251–1260.
Scoville EA, Konijeti GG, Nguyen DD, et al. Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors. Inflamm Bowel Dis. 2014; 20: 631–636.
Ra G, Thanabalan R, Ratneswaran S, et al. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J Crohn’s Colitis 2013; 7: e479–e485.
Loftus EV Jr, Friedman HS, Delgado DJ, et al. Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflamm Bowel Dis. 2009; 15: 566–575.
Zittan E, Wong-Chong N, Ma GW, et al. Modified two-stage ileal pouch-anal anastomosis results in lower rate of anastomotic leak compared with traditional two-stage surgery for ulcerative colitis. J Crohn’s Colitis 2016; 10: 766–772.
Mege D, Colombo F, Stellingwerf ME, et al. Risk factors for small bowel obstruction after laparoscopic ileal pouch-anal anastomosis for inflammatory bowel disease: a multivariate analysis in four Expert Centres in Europe. J Crohn’s Colitis 2019; 13: 294–301.
Lightner AL, Mathis KL, Dozois EJ, et al. Results at up to 30 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Inflamm Bowel Dis. 2017; 23: 781–790.
Nguyen N, Zhang B, Holubar SD, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2019; 5: CD001176.
Schluender SJ, Mei L, Yang H, et al. Can a meta-analysis answer the question: is mucosectomy and handsewn or double-stapled anastomosis better in ileal pouch-anal anastomosis? Am J Surg. 2006; 72: 912–916.
Ishii H, Kawai K, Hata K, et al. Comparison of functional outcomes of patients who underwent hand-sewn or stapled ileal pouch-anal anastomosis for ulcerative colitis. Int Surg. 2015; 100: 1169–1176.
Ahmed Ali U, Keus F, Heikens JT, et al. Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst Rev. 2009; (1): CD006267. http://hdl.handle.net/2066/81527.
Andersson P, Norblad R, Söderholm JD, et al. Ileorectal anastomosis in comparison with ileal pouch anal anastomosis in reconstructive surgery for ulcerative colitis – a single institution experience. J Crohn’s Colitis 2014; 8: 582–589.
Annibali R, Oresland T, Hultén L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis Colon Rectum 1994; 37: 321–329.
Tekkis PP, Fazio VW, Lavery IC, et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg. 2005; 241: 262–268.
Hurst RD, Molinari M, Chung TP, et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg. 1996; 131: 497–500; discussion 501–502.
Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001; 7: 301–305.
Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal-pouch anal anastomosis for ulcerative colitis. Cochrane Database Syst Rev. 2010; 6: CD001176.
Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther. 2007; 25: 1231–1236.
Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999; 13: 713–718.